Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronidase to Extend Insulin Infusion Set Wear
NCT02199028Phase 1Completed
- Sponsor
- Stanford University
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recombinant human hyaluronidase PH20 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Stanford University. Primary endpoint: Duration of Insulin Infusion Set Wear as a Measure of the Effect of Hyaluronidase Treatment at 4 weeks. Started Jul 2014; status: completed.
02
Drugs
recombinant human hyaluronidase PH20
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02199028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199028.